Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Olink Holding AB (publ) is a diagnostics & research business based in the US. Olink Holding AB publ shares (OLK) are listed on the NASDAQ and all prices are listed in US Dollars. Olink Holding AB publ employs 214 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$29.88|
|52-week range||$22.30 - $42.20|
|50-day moving average||$27.32|
|200-day moving average||$32.28|
|Wall St. target price||$43.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.37|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||3.03%|
|1 month (2021-09-24)||21.17%|
|3 months (2021-07-23)||-19.18%|
|6 months (2021-04-23)||-23.40%|
|1 year (2020-10-20)||N/A|
|2 years (2019-10-20)||N/A|
|3 years (2018-10-20)||N/A|
|5 years (2016-10-20)||N/A|
Valuing Olink Holding AB publ stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Olink Holding AB publ's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Olink Holding AB publ's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.3 million.
The EBITDA is a measure of a Olink Holding AB publ's overall financial performance and is widely used to measure a its profitability.
To put Olink Holding AB publ's EBITDA into context you can compare it against that of similar companies.
|Revenue TTM||$69.5 million|
|Gross profit TTM||$36.6 million|
|Return on assets TTM||-0.87%|
|Return on equity TTM||-2.68%|
|Market capitalisation||$3.5 billion|
TTM: trailing 12 months
There are currently 2.0 million Olink Holding AB publ shares held short by investors – that's known as Olink Holding AB publ's "short interest". This figure is 10.8% up from 1.8 million last month.
There are a few different ways that this level of interest in shorting Olink Holding AB publ shares can be evaluated.
Olink Holding AB publ's "short interest ratio" (SIR) is the quantity of Olink Holding AB publ shares currently shorted divided by the average quantity of Olink Holding AB publ shares traded daily (recently around 333824.67320261). Olink Holding AB publ's SIR currently stands at 6.12. In other words for every 100,000 Olink Holding AB publ shares traded daily on the market, roughly 6120 shares are currently held short.
To gain some more context, you can compare Olink Holding AB publ's short interest ratio against those of similar companies.
However Olink Holding AB publ's short interest can also be evaluated against the total number of Olink Holding AB publ shares, or, against the total number of tradable Olink Holding AB publ shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Olink Holding AB publ's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Olink Holding AB publ shares in existence, roughly 20 shares are currently held short) or 0.0598% of the tradable shares (for every 100,000 tradable Olink Holding AB publ shares, roughly 60 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Olink Holding AB publ.
Find out more about how you can short Olink Holding AB publ stock.
We're not expecting Olink Holding AB publ to pay a dividend over the next 12 months.
You may also wish to consider:
Olink Holding AB (publ) provides various products and services for academic, government, biopharmaceutical, biotechnology, and other institutions focused on life science research. Its products include Olink Explore for cardiovascular and metabolic diseases, oncology, neurology, or inflammation; Olink Target product line; and Olink Focus product line consists of custom developed solutions for customers that have identified a small number of proteins of interest to focus on. The company's products also comprise Olink NPX Manager, a purpose-built software that enable users to import data, validate data quality, and normalize for subsequent statistical analysis; and Olink Insight, a cloud platform for data visualization and statistical analysis of normalized protein expression (NPX) data. In addition, it provides Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and bioinformatics services. The company sells its products and services through its own direct sales force in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Knilo HoldCo AB and changed its name to Olink Holding AB (publ) in January 2021. Olink Holding AB (publ) was founded in 2016 and is headquartered in Uppsala, Sweden.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.